In this study, we report that an orally bioavailable PP2A activator SMAP has anti-HCC activity in vitro and in vivo through its ability to simultaneously inhibit PP2A substrates Akt and ERK activity, resulting in cell cycle arrest and ultimately cell death. This evidence concerns the gene PTPA and hepatocellular carcinoma.